Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y1UL
|
|||
| Former ID |
DNC010328
|
|||
| Drug Name |
(E)-3-(4-hydroxybenzylidene)indolin-2-one
|
|||
| Synonyms |
CHEMBL103307; (E)-3-(4-hydroxybenzylidene)indolin-2-one; 3-(4-Hydroxybenzylidenyl)indolin-2-one; SCHEMBL16442341; BDBM50131995; ZINC12568108; AKOS001309473; 3-(4-hydroxybenzylidene)indolin-2-one; NCGC00343741-01; ACM293302144; AB00756566-01
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H11NO2
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=CC3=CC=C(C=C3)O)C(=O)N2
|
|||
| InChI |
1S/C15H11NO2/c17-11-7-5-10(6-8-11)9-13-12-3-1-2-4-14(12)16-15(13)18/h1-9,17H,(H,16,18)/b13-9+
|
|||
| InChIKey |
PLAOAGFXNCEZMZ-UKTHLTGXSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Proto-oncogene c-Ret (RET) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Endocytosis | |||
| Pathways in cancer | ||||
| Thyroid cancer | ||||
| Central carbon metabolism in cancer | ||||
| Pathway Interaction Database | Signaling events regulated by Ret tyrosine kinase | |||
| Posttranslational regulation of adherens junction stability and dissassembly | ||||
| WikiPathways | SIDS Susceptibility Pathways | |||
| Dopaminergic Neurogenesis | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors. Bioorg Med Chem. 2010 Feb 15;18(4):1482-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.